Characterization of the immune response induced by pertussis OMVs-based vaccine

Vaccine

Volumn 34, Issue 28, 2016, Pages 3303-3309

  Bottero, D ^a   Gaillard, M E ^a   Zurita, E ^a   Moreno, G ^b   Martinez, D Sabater ^a   Bartel, E ^a   Bravo, S ^a   Carriquiriborde, F ^a   Errea, A ^b   Castuma, C ^a   Rumbo, M ^b   Hozbor, D ^a  

^a FACULTAD DE CIENCIAS EXACTAS   (Argentina)

^b Universidad Nacional de La Plata   (Argentina)

Author keywords

Acellular vaccine; Bordetella pertussis; OMVs; Protection; Whooping cough

Indexed keywords

ANTISERUM; DIPHTHERIA PERTUSSIS TETANUS VACCINE; GAMMA INTERFERON; INTERLEUKIN 17; PERTUSSIS VACCINE; ACELLULAR VACCINE; BACTERIUM ANTIBODY; IL6 PROTEIN, HUMAN; INTERLEUKIN 6;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ARTICLE; BORDETELLA PERTUSSIS; CELL STIMULATION; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MEMBRANE VESICLE; MOUSE; NONHUMAN; OUTER MEMBRANE VESICLE; PERTUSSIS; PRIORITY JOURNAL; SPLEEN CELL; TH1 CELL; TH17 CELL; TH2 CELL; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL CULTURE; CYTOLOGY; HUMAN; IMMUNOLOGY; PHAGOCYTOSIS; RAW 264.7 CELL LINE; SPLEEN; WHOOPING COUGH;

ANIMALS; ANTIBODIES, BACTERIAL; BORDETELLA PERTUSSIS; CELLS, CULTURED; FEMALE; HUMANS; IMMUNE SERA; IMMUNITY, HUMORAL; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-6; MICE; MICE, INBRED BALB C; PERTUSSIS VACCINE; PHAGOCYTOSIS; RAW 264.7 CELLS; SPLEEN; TH17 CELLS; VACCINES, ACELLULAR; WHOOPING COUGH;

EID: 84971350767     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.04.079     Document Type: Article

References (47)

1. Gregory D.S. Pertussis: a disease affecting all ages. Am Fam Phys 2006, 74:420-426.
2. Edwards K.M. Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination. Pediatr Infect Dis J 2005, 24:S104-S108.
3. Amirthalingam G., Gupta S., Campbell H. Pertussis immunisation and control in England and Wales, 1957 to 2012: a historical review. Euro Surveill 2013, 18.
4. Cody C.L., Baraff L.J., Cherry J.D., Marcy S.M., Manclark C.R. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 1981, 68:650-660.
5. Jefferson T., Rudin M., DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine 2003, 21:2003-2014.
6. Klein N.P. Licensed pertussis vaccines in the United States. History and current state. Hum Vaccines Immunother 2014, 10:2684-2690.
7. Sato Y., Sato H. Development of acellular pertussis vaccines. Biologicals 1999, 27:61-69.
8. Clark T.A. Changing pertussis epidemiology: everything old is new again. J Infect Dis 2014, 209:978-981.
9. Lam C., Octavia S., Ricafort L., Sintchenko V., Gilbert G.L., Wood N., et al. Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia. Emerg Infect Dis 2014, 20:626-633.
10. Safarchi A., Octavia S., Luu L.D., Tay C.Y., Sintchenko V., Wood N., et al. Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model. Vaccine 2015, 33:6277-6281.
11. Ryan M., Murphy G., Ryan E., Nilsson L., Shackley F., Gothefors L., et al. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 1998, 93:1-10.
12. Mascart F., Verscheure V., Malfroot A., Hainaut M., Pierard D., Temerman S., et al. Bordetella pertussis infection in 2-month-old infants promotes type 1 T cell responses. J Immunol 2003, 170:1504-1509.
13. Mascart F., Hainaut M., Peltier A., Verscheure V., Levy J., Locht C. Modulation of the infant immune responses by the first pertussis vaccine administrations. Vaccine 2007, 25:391-398.
14. Rowe J., Yerkovich S.T., Richmond P., Suriyaarachchi D., Fisher E., Feddema L., et al. Th2-associated local reactions to the acellular diphtheria-tetanus-pertussis vaccine in 4- to 6-year-old children. Infect Immun 2005, 73:8130-8135.
15. Vermeulen F., Verscheure V., Damis E., Vermeylen D., Leloux G., Dirix V., et al. Cellular immune responses of preterm infants after vaccination with whole-cell or acellular pertussis vaccines. Clin Vaccine Immunol 2010, 17:258-262.
16. Ross P.J., Sutton C.E., Higgins S., Allen A.C., Walsh K., Misiak A., et al. Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLOS Pathog 2013, 9:e1003264.
17. Warfel J.M., Zimmerman L.I., Merkel T.J. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci USA 2014, 111:787-792.
18. Klein N.P., Bartlett J., Fireman B., Rowhani-Rahbar A., Baxter R. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics 2013, 131:e1716-e1722.
19. Asensio C.J., Gaillard M.E., Moreno G., Bottero D., Zurita E., Rumbo M., et al. Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate. Vaccine 2011, 29:1649-1656.
20. Gaillard M.E., Bottero D., Errea A., Ormazabal M., Zurita M.E., Moreno G., et al. Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes. Vaccine 2014, 32:931-937.
21. Roberts R., Moreno G., Bottero D., Gaillard M.E., Fingermann M., Graieb A., et al. Outer membrane vesicles as acellular vaccine against pertussis. Vaccine 2008, 26:4639-4646.
22. Stainer D.W., Scholte M.J. A simple chemically defined medium for the production of phase I Bordetella pertussis. J Gen Microbiol 1970, 63:211-220.
23. Hozbor D., Rodriguez M.E., Fernandez J., Lagares A., Guiso N., Yantorno O. Release of outer membrane vesicles from Bordetella pertussis. Curr Microbiol 1999, 38:273-278.
24. Asensio C.J., Gaillard M.E., Moreno G., Bottero D., Zurita E., Rumbo M., et al. Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate. Vaccine 2010, 29:1649-1656.
25. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
26. WHO Annex 6. Recommendations for whole-cell pertussis vaccine 2007, WHO.
27. Stoddard M.B., Pinto V., Keiser P.B., Zollinger W. Evaluation of a whole-blood cytokine release assay for use in measuring endotoxin activity of group B Neisseria meningitidis vaccines made from lipid A acylation mutants. Clin Vaccine Immunol 2010, 17:98-107.
28. Bottero D., Gaillard M.E., Basile L.A., Fritz M., Hozbor D.F. Genotypic and phenotypic characterization of Bordetella pertussis strains used in different vaccine formulations in Latin America. J Appl Microbiol 2012, 112:1266-1276.
29. Bottero D., Gaillard M.E., Fingermann M., Weltman G., Fernandez J., Sisti F., et al. Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains. Clin Vaccine Immunol 2007, 14:1490-1498.
30. Ormazabal M., Bartel E., Gaillard M.E., Bottero D., Errea A., Zurita M.E., et al. Characterization of the key antigenic components of pertussis vaccine based on outer membrane vesicles. Vaccine 2014, 32:6084-6090.
31. Brummelman J., Wilk M.M., Han W.G., van Els C.A., Mills K.H. Roads to the development of improved pertussis vaccines paved by immunology. Pathog Dis 2015, 73:ftv067.
32. Mills K.H., Barnard A., Watkins J., Redhead K. Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect Immun 1993, 61:399-410.
33. Warfel J.M., Merkel T.J. Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates. Mucosal Immunol 2013, 6:787-796.
34. Warfel J.M., Zimmerman L.I., Merkel T.J. Comparison of three whole-cell pertussis vaccines in the baboon model of pertussis. Clin Vaccine Immunol 2015, 23:47-54.
35. Casadevall A., Dadachova E., Pirofski L.A. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004, 2:695-703.
36. Casadevall A., Pirofski L.A. New concepts in antibody-mediated immunity. Infect Immun 2004, 72:6191-6196.
37. Hellwig S.M., van Oirschot H.F., Hazenbos W.L., van Spriel A.B., Mooi F.R., van De Winkel J.G. Targeting to Fcgamma receptors, but not CR3 (CD11b/CD18), increases clearance of Bordetella pertussis. J Infect Dis 2001, 183:871-879.
38. Hellwig S.M., Rodriguez M.E., Berbers G.A., van de Winkel J.G., Mooi F.R. Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J Infect Dis 2003, 188:738-742.
39. Weingart C.L., Keitel W.A., Edwards K.M., Weiss A.A. Characterization of bactericidal immune responses following vaccination with acellular pertussis vaccines in adults. Infect Immun 2000, 68:7175-7179.
40. Casadevall A., Pirofski L.A. A new synthesis for antibody-mediated immunity. Nat Immunol 2012, 13:21-28.
41. Sarvas H., Seppala I., Kurikka S., Siegberg R., Makela O. Half-life of the maternal IgG1 allotype in infants. J Clin Immunol 1993, 13:145-151.
42. van den Berg B.M., David S., Beekhuizen H., Mooi F.R., van Furth R. Protection and humoral immune responses against Bordetella pertussis infection in mice immunized with acellular or cellular pertussis immunogens. Vaccine 2000, 19:1118-1128.
43. Mooi F.R., de Greeff S.C. The case for maternal vaccination against pertussis. Lancet Infect Dis 2007, 7:614-624.
44. Valentini D., Ferrara G., Advani R., Hallander H.O., Maeurer M.J. Serum reactome induced by Bordetella pertussis infection and Pertussis vaccines: qualitative differences in serum antibody recognition patterns revealed by peptide microarray analysis. BMC Immunol 2015, 16:40.
45. Zhu Y.Z., Cai C.S., Zhang W., Guo H.X., Zhang J.P., Ji Y.Y., et al. Immunoproteomic analysis of human serological antibody responses to vaccination with whole-cell pertussis vaccine (WCV). PLoS ONE 2010, 5:e13915.
46. Raeven R.H., van der Maas L., Tilstra W., Uittenbogaard J.P., Bindels T.H., Kuipers B., et al. Immunoproteomic profiling of Bordetella pertussis outer membrane vesicle vaccine reveals broad and balanced humoral immunogenicity. J Proteome Res 2015, 14:2929-2942.
47. Gaillard M.E., Bottero D., Moreno G., Rumbo M., Hozbor D. Strategies and new developments to control pertussis, an actual health problem. Pathog Dis 2015, 73:ftv059.